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Introduction
Hepatoblastoma is a rare hepatic malignancy that is seen
in Familial Adenomatous Polyposis (FAP). The occur-
rence is four hundred fold higher than the general popu-
lation [1]. Hepatoblastoma is generally treatable with
surgery; in addition it is highly responsive to chemother-
apy. While the literature reports on this extracolonic
manifestation of FAP, no screening recommendations
e x i s t ,t h i sm a yb ed u et ot h er a r i t yo ft h ec o n d i t i o na n d
paucity of published literature. Our aim was to examine
and assess the number of hepatoblastoma patients, their
associated demographics and the outcome of disease.
Methods
Patients with FAP and hepatoblastomas were identified
from a comprehensive polyposis database using Colo-
gene© software. Variables that we assessed were age at
diagnosis, hepatoblastoma characteristics, outcome,
colonic / duodenal polyposis and management along
with other extracolonics present.
Result
Five patients, all male, from five families were diagnosed
with hepatoblastomas in the last 23 years. The mean age at
diagnosis was 17 months (+/
_ 7 standard deviation). Genetic
testing was available on 3/5 patients and were all 3 prime.
No patient had a family history of hepatoblastoma, but 4/5
did have a family history of FAP. 4/5 presented with abdom-
inal distention, tenderness or firmness. The youngest patient
was diagnosed secondary to recurrent fevers. All patients
had chemotherapy, 4/5 had resections of the hepatic tumor.
3/5 patients experienced total remission; one patient had
two recurrences and a subsequent small bowel transplant
due to desmoids disease. One underprivileged patient had
late access to medical care due to poor socioeconomic
status. He was diagnosed with an unresectable tumor and
pulmonary metastasis disease, even after chemotherapy he
died 6 months later. The median follow up time was
10 years (range 0.5 to 23). 2/5 patients have bilateral high
frequency hearing loss from chemotoxicity resulting in the
use of hearing aides. One patient had cardiac toxicity, he is
being followed yearly. One patient suffered from short
stature, pubertal delay secondary to chemotherapy.
Conclusion
Our results are consistent with the published data on
FAP. Patients with hepatoblastomas are generally young
males with APC mutations in the 3 prime areas. This
should prompt consideration of abdominal imaging in
children with this constellation of genotype and hepato-
blastoma demographics, regardless of family history.
Further research into early detection of this possible
mode of neoplasm is warranted.
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